TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
DUBLIN, Ireland, Aug. 24, 2017 -- Horizon Pharma plc (Nasdaq:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced today that the Company will present at the Morgan Stanley 15th Annual Global Healthcare Conference at 10:30 a.m. ET on September 13, 2017 in New York City, NY.
The conference presentation will be webcast live and may be accessed by visiting Horizon's investor relations section of the website at http://ir.horizon-pharma.com. A replay of the webcast will be available for the event.
About Horizon Pharma plc
Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. The Company markets 11 medicines through its orphan, rheumatology and primary care business units. For more information, please visit www.horizonpharma.com. Follow @HZNPplc on Twitter or view careers on our LinkedIn page.
Contacts: Investors: Tina Ventura Senior Vice President, Investor Relations [email protected] Ruth Venning Executive Director, Investor Relations [email protected] U.S. Media: Geoff Curtis Senior Vice President, Corporate Affairs & Chief Communications Officer [email protected] Ireland Media: Ray Gordon Gordon MRM [email protected]
